Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
WILMINGTON, Del., March 11, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)?
- Did you purchase your shares between March 5, 2015 and September 8, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ:TTPH) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of Tetraphase between July 21, 2015 and January 13, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Tetraphase during the Class Period, or purchased shares prior to the Class Period and still hold Tetraphase, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/tetraphase-pharmaceuticals-inc-ttph.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
